{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16","value":"51.83"},{"comment":"Unable to calculate geometric coefficient of variation due to low number of participants","groupId":"OG001","spread":"NA","value":"40.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Maximum observed serum concentration of Analyte BMS-986016","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W","id":"OG000","title":"Part A - Flat Dosing (AF)"},{"description":"Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W","id":"OG001","title":"Part A - Age/Weight-based Dosing (AW)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Maximum Serum Concentration (Cmax)","type":"PRIMARY","unitOfMeasure":"ug/mL"}